Evidence supporting a role for SFKs in immunosuppression during cancer progression is provided by studies on chronic myeloid leukemia, where Dasatinib treatment led to Treg inhibition, reduced the abundance of MDSCs, and increased both NK cell differentiation and Granzyme B-expressing CD4+ and CD8+ memory T cells [138–140]. The gene discussed is CD8A; the disease is cancer.